Assignee
ALNYLAM PHARMACEUTICALS INC
US·341 granted patents·374 pending applications·4,334 citations·filing 2003–2025
Top patents by PatentIndex Score
715 records- 0199US11525138B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 13, 2022·7 cites·28 claims
- 0299US11130953B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Sep 28, 2021·8 cites·30 claims
- 0399US10806791B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Oct 20, 2020·14 cites·12 claims
- 0499US9796974B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Oct 24, 2017·119 cites·30 claims
- 0599US9352048B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted May 31, 2016·112 cites·20 claims
- 0699US8344125B2Modified iRNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2009·Granted Jan 1, 2013·103 cites·20 claims
- 0799US7749978B2Compositions and methods for inhibiting expression of Huntingtin geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted Jul 6, 2010·113 cites·26 claims
- 0899US7718629B2Compositions and methods for inhibiting expression of Eg5 geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted May 18, 2010·241 cites·33 claims
- 0999US7605251B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted Oct 20, 2009·160 cites·20 claims
- 1099US7582745B2Compositions and methods for inhibiting expression of Nav1.8 geneALNYLAM PHARMACEUTICALS INC·Filed 2006·Granted Sep 1, 2009·152 cites·11 claims
- 1199US7423142B2Compositions and methods for inhibiting expression of anti-apoptotic genesALNYLAM PHARMACEUTICALS INC·Filed 2005·Granted Sep 9, 2008·118 cites·5 claims
- 1299US7320965B2Compositions and methods for inhibiting expression of Huntingtin geneALNYLAM PHARMACEUTICALS INC·Filed 2006·Granted Jan 22, 2008·208 cites·8 claims
- 1398US11866709B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 9, 2024·3 cites·29 claims
- 1498US11840692B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·3 cites·29 claims
- 1598US11834662B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·3 cites·29 claims
- 1698US11679158B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jun 20, 2023·7 cites·13 claims
- 1798US11633479B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·24 claims
- 1898US11633480B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Apr 25, 2023·11 cites·28 claims
- 1998US11612657B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Mar 28, 2023·9 cites·30 claims
- 2098US11590229B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Feb 28, 2023·11 cites·29 claims
- 2198US11406716B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Aug 9, 2022·8 cites·21 claims
- 2298US11382979B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jul 12, 2022·18 cites·30 claims
- 2398US11332743B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 17, 2022·6 cites·26 claims
- 2498US11306315B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 2598US11306314B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 2698US11306316B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
- 2798US11246933B1Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Feb 15, 2022·30 cites·28 claims
- 2898US11110174B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Sep 7, 2021·10 cites·20 claims
- 2998US10668170B2Modified RNAi agentsALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·22 cites·22 claims
- 3098US10612024B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·15 cites·35 claims
- 3198US10612027B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Apr 7, 2020·26 cites·25 claims
- 3298US10369226B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Aug 6, 2019·25 cites·42 claims
- 3398US10233448B2Modified double-stranded RNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 19, 2019·37 cites·40 claims
- 3498US9867882B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Jan 16, 2018·33 cites·29 claims
- 3598US9771591B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Sep 26, 2017·22 cites·34 claims
- 3698US9399775B2RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jul 26, 2016·51 cites·36 claims
- 3798US9322018B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 26, 2016·36 cites·41 claims
- 3898US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
- 3998US9061063B2Biodegradable lipids for the delivery of active agentsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Jun 23, 2015·41 cites·32 claims
- 4098US8828956B2Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Sep 9, 2014·224 cites·16 claims
- 4198US8809516B2Therapeutic compositionsALNYLAM PHARMACEUTICALS INC·Filed 2012·Granted Aug 19, 2014·43 cites·22 claims
- 4298US7745608B2Modified iRNA agentsALNYLAM PHARMACEUTICALS INC·Filed 2004·Granted Jun 29, 2010·129 cites·43 claims
- 4398US7737265B2RNAi modulation of HIF-1 and therapeutic uses thereofALNYLAM PHARMACEUTICALS INC·Filed 2006·Granted Jun 15, 2010·122 cites·27 claims
- 4498US7582744B2Chemically modified oligonucleotidesALNYLAM PHARMACEUTICALS INC·Filed 2005·Granted Sep 1, 2009·177 cites·23 claims
- 4597US11286486B2Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseasesALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Mar 29, 2022·8 cites·28 claims
- 4697US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
- 4797US11015201B2Angiotensinogen (AGT) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 25, 2021·6 cites·15 claims
- 4897US10851377B2Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorderALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Dec 1, 2020·4 cites·30 claims
- 4997US10557139B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 11, 2020·15 cites·20 claims
- 5097US10550390B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 4, 2020·15 cites·20 claims
Showing the top 50 of 715 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ALNYLAM PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →